Psychobiology Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, Department of Health and Human Services, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (T.H., G.T., T.A.K., J.L.K.); and Behavioral Biology Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland (P.L.S.).
J Pharmacol Exp Ther. 2013 Oct;347(1):20-9. doi: 10.1124/jpet.113.207522. Epub 2013 Aug 1.
A previous study showed that cocaine self-administration induced dopamine-independent reinforcing effects of σ agonists mediated by their selective actions at σ1 receptors (σ1Rs), which are intracellularly mobile chaperone proteins implicated in abuse-related effects of stimulants. The present study assessed whether the induction was specific to self-administration of cocaine. Rats were trained to self-administer the dopamine releaser, d-methamphetamine (0.01-0.32 mg/kg per injection), the μ-opioid receptor agonist, heroin (0.001-0.032 mg/kg per injection), and the noncompetitive N-methyl-d-aspartate receptor/channel antagonist ketamine (0.032-1.0 mg/kg per injection). As with cocaine, self-administration of d-methamphetamine induced reinforcing effects of the selective σ1R agonists PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate hydrochloride] and (+)-pentazocine (0.032-1.0 mg/kg per injection, each). In contrast, neither self-administration of heroin nor ketamine induced PRE-084 or (+)-pentazocine (0.032-10 mg/kg per injection, each) self-administration. Although the σ1R agonists did not maintain responding in subjects with histories of heroin or ketamine self-administration, substitution for those drugs was obtained with appropriate agonists (e.g., remifentanil, 0.1-3.2 µg/kg per injection, for heroin and (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ((+)-MK 801; dizocilpine), 0.32-10.0 µg/kg per injection, for ketamine). The σR antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008; 1.0-10 mg/kg) dose-dependently blocked PRE-084 self-administration but was inactive against d-methamphetamine, heroin, and ketamine. In contrast, PRE-084 self-administration was affected neither by the dopamine receptor antagonist (+)-butaclamol (10-100 μg/kg) nor by the opioid antagonist (-)-naltrexone (1.0-10 mg/kg), whereas these antagonists were active against d-methamphetamine and heroin self-administration, respectively. The results indicate that experience specifically with indirect-acting dopamine agonists induces reinforcing effects of previously inactive σ1R agonists. It is further suggested that induced σ1R reinforcing mechanisms may play an essential role in treatment-resistant stimulant abuse, suggesting new approaches for the development of effective medications for its treatment.
先前的研究表明,可卡因自我给药诱导了 σ 激动剂的多巴胺非依赖性强化作用,这是由它们在 σ1 受体(σ1Rs)上的选择性作用介导的,σ1Rs 是与兴奋剂相关的滥用效应有关的细胞内移动伴侣蛋白。本研究评估了这种诱导是否特异性地与可卡因的自我给药有关。大鼠被训练自我给予多巴胺释放剂 d-苯丙胺(每注射 0.01-0.32mg/kg)、μ-阿片受体激动剂海洛因(每注射 0.001-0.032mg/kg)和非竞争性 N-甲基-D-天冬氨酸受体/通道拮抗剂氯胺酮(每注射 0.032-1.0mg/kg)。与可卡因一样,d-苯丙胺的自我给药诱导了选择性 σ1R 激动剂 PRE-084[2-(4-吗啉乙基)-1-苯基环己烷羧酸盐酸盐]和 (+)-戊唑辛(每注射 0.032-1.0mg/kg)的强化作用。相比之下,海洛因或氯胺酮的自我给药都没有诱导 PRE-084 或 (+)-戊唑辛(每注射 0.032-10mg/kg)的自我给药。尽管 σ1R 激动剂在有海洛因或氯胺酮自我给药史的受试者中不能维持反应,但适当的激动剂(例如,瑞芬太尼,每注射 0.1-3.2μg/kg,用于海洛因和(5S,10R)-(+)-5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺((+)-MK 801;地佐辛),每注射 0.32-10.0μg/kg,用于氯胺酮)可以替代这些药物。σR 拮抗剂 N-[2-(3,4-二氯苯基)乙基]-N-甲基-2-(1-吡咯烷基)乙基胺二氢溴化物(BD 1008;1.0-10mg/kg)剂量依赖性地阻断了 PRE-084 的自我给药,但对 d-苯丙胺、海洛因和氯胺酮没有活性。相比之下,多巴胺受体拮抗剂(+)-布他卡林(10-100μg/kg)和阿片受体拮抗剂(-)-纳曲酮(1.0-10mg/kg)都不影响 PRE-084 的自我给药,而这些拮抗剂分别对 d-苯丙胺和海洛因的自我给药有活性。结果表明,与间接作用的多巴胺激动剂的经验特异性诱导了以前无效的 σ1R 激动剂的强化作用。进一步表明,诱导的 σ1R 强化机制可能在治疗抵抗性兴奋剂滥用中发挥重要作用,为治疗这种疾病的有效药物的开发提供了新的方法。